BETHESDA, Md.--(BUSINESS WIRE)--BrainScope today announced its second consecutive nomination for the 2018 Annual Prix Galien USA Awards for “Best Medical Technology” product. Its flagship BrainScope One product is a multi-modal, comprehensive, handheld capability to help clinicians objectively and rapidly assess and triage head injured patients directly at the point of care.
BrainScope’s innovative technology addresses a vast market need for the global epidemic of mild head injury, which impacts more people each year than stroke and heart failure combined. BrainScope One is the first FDA-cleared medical device to offer capabilities to assess the full spectrum of brain injury – from concussions (functional abnormality) to brain bleeds (structural injury). Recent white papers authored by third parties have shown the potential for BrainScope One to decrease unnecessary head CT scans by one-third, to reduce head injury referrals to emergency departments by up to 75% and to reduce healthcare costs for payers and patients by over 30%.
The Prix Galien USA Awards are bestowed by the Galien Foundation which “…fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. It is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.” Nominees are evaluated by a committee of twelve esteemed scientific leaders from the biopharmaceutical industry and academia, including four Noble Laureates. As one of ten nominees for “Best Medical Technology”, BrainScope stands among prominent medical device companies such as Abbott, Boston Scientific and Medtronic.
BrainScope CEO Michael Singer stated, “It is a tremendous honor to be nominated for the Prix Galien USA award, and to be nominated twice is a testament to our team’s efforts in creating tangible scientific and health impacts with the creation and commercialization of BrainScope One. We are grateful to the Galien Foundation for its recognition of our innovation and dedication to providing the public with objective and comprehensive neurological assessment capabilities addressing the global brain injury problem.”
BrainScope’s mission is to revolutionize the rapid and objective assessment of brain-related conditions, starting with concussion and mild traumatic brain injury, utilizing multiple integrated assessment capabilities, artificial intelligence (AI) and digitization within a culture of quality, excellence and entrepreneurialism. The Company’s first product introduced in 2017, BrainScope One (cleared as Ahead 300), incorporates a multi-modal panel of capabilities including EEG-based technology that is non-invasive for mildly presenting head injured patients, 18-85 years old, within 3 days after injury and is not a replacement to CT scan. BrainScope’s technology platform integrates databases of thousands of brainwave recordings with AI technology and miniaturized hardware and disposable headset sensors, all of which are covered by an extensive intellectual property portfolio of over 100 issued and pending patents globally. BrainScope has received five FDA clearances and ISO 13485:2003 Certification. It has 24 peer-reviewed publications on its technology. BrainScope has partnered with the U.S. Department of Defense for the development of its TBI assessment technology, and BrainScope One is currently being fielded by the U.S. military, both stateside and internationally. BrainScope One is also being utilized in a cross-section of market segments including: urgent care and occupational health clinics; concussion clinics; hospital emergency rooms; university sports and student health centers; professional sports; and pharmaceutical clinical trials. BrainScope has been the recipient of several prestigious awards, including the Frost & Sullivan 2017 Best Practices Award for New Product Innovation in the Traumatic Brain Injury Assessment Solutions Market, was a two-time winner of the GE-NFL Head Health Challenge, and has now received two nominations for the Prix Galien Best Medical Technology, regarded as the equivalent of the Nobel Prize for medical devices. For more information, please visit www.brainscope.com.